PSMA引导的前列腺局灶立体定向再照射试验中期结果
这项前瞻性单中心试验纳入25例根治性放疗后活检证实孤立前列腺复发、且多参数MRI与68Ga-PSMA PET/CT一致、复发时PSA<15 ng/mL的患者,采用LINAC-SBRT行PSMA引导的局灶再照射,前18例36 Gy/6次、后续38 Gy/6次。中位随访25个月,急性1-2级GU毒性分别为24%和4%,1例3级急性GI毒性;24例完成12个月PSMA PET/CT者中23例(92%)达完全代谢缓解,2年生化无失败率80%。
要点
- PSMA引导的LINAC-SBRT前列腺局灶再照射可行且安全,毒性低。
- 12个月PSMA PET/CT完全代谢缓解率达92%(23/24)。
- 2年生化无失败率为80%,生化失败多伴局部复发。
核心结论
- PSMA引导的挽救性前列腺局灶再照射采用LINAC-SBRT可行且安全,在严格筛选患者中短期局部与生化控制良好。
研究设计与样本
- 前瞻性单中心试验(ACTRN12617000035325),2016年3月至2019年3月纳入25例活检证实孤立前列腺复发患者。
- 入组要求多参数MRI与68Ga-PSMA PET/CT表现一致,复发时PSA<15 ng/mL。
- 序贯剂量递增:前18例36 Gy/6次隔日照射,后续患者38 Gy/6次(前提为毒性可接受)。
主要发现
- 中位年龄72岁(范围62-83),首程放疗至挽救SBRT中位间隔8.3年(范围4.5-13.6),再照射时中位PSA 4.1(范围1.1-16.6),中位随访25个月(范围13-46)。
- 急性1级和2级GU毒性分别见于6例(24%)和1例(4%),急性1级GI毒性8%,1例(4%)急性3级GI毒性(直肠溃疡,位于水凝胶上方)。
- 晚期1级和2级GU毒性分别为28%和4%,晚期1级GI毒性8%,无≥2级晚期GI毒性。
- 24例按方案完成12个月68Ga-PSMA PET/CT,其中23例(92%)达完全代谢缓解。
- 2年生化无失败率80%,4例生化失败中3例伴局部复发。
临床怎么用
- 对根治性放疗后孤立前列腺复发、PSMA PET/CT与MRI一致且PSA<15 ng/mL的患者,可考虑PSMA引导的LINAC-SBRT局灶再照射。
- 再照射需关注GU及GI毒性,尤其直肠溃疡风险,并可按序贯剂量递增方案(36 Gy/6次或38 Gy/6次)实施。
- 短期随访中PSMA PET/CT代谢缓解与生化控制较好,支持在严格筛选人群中使用。
局限性
- 单中心、小样本(25例)前瞻性试验,随访时间短(中位25个月)。
- 包含序贯剂量递增设计,两种剂量组样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the feasibility, toxicity, and preliminary outcomes (metabolic and biochemical) of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-directed focal prostate reirradiation using linear accelerator (LINAC)-based stereotactic body radiation treatment (SBRT). METHODS AND MATERIALS: From March 2016 to March 2019, 25 patients were enrolled in a prospective single institution trial (ACTRN12617000035325). Eligibility criteria included patients with biopsy proven isolated prostate recurrence after definitive irradiation, with concordant multiparametric MRI and 68Ga-PSMA PET/CT findings, and a prostate-specific antigen of less than 15 ng/mL at the time of recurrence. The study included a sequential dose escalation component with the first 18 patients receiving 36 Gy in 6 fractions on alternate days with subsequent patients receiving 38 Gy in 6 fractions assuming acceptable toxicity. RESULTS: Median age was 72 years (range, 62-83) with a median time between first radiation treatment and salvage SBRT of 8.3 years (range, 4.5- 13.6). Median prostate-specific antigen at reirradiation was 4.1 (range, 1.1-16.6). The median follow-up was 25 months (range, 13-46). Acute grade 1 and 2 genitourinary (GU) toxicity occurred in 6 (24%) and 1 (4%) men, respectively. Acute grade 1 gastrointestinal (GI) toxicity occurred in 8% with one acute grade 3 GI toxicity (4%) due to a rectal ulcer overlying the hydrogel. Late grade 1 and 2 GU toxicity occurred in 28% and 4%. Late grade 1 GI toxicity occurred in 8% with no grade 2 or greater toxicity. Twenty-four patients have undergone per-protocol 12-month 68Ga-PSMA PET/CT, of which 23 (92%) demonstrated a complete metabolic response. Biochemical freedom from failure was 80% at 2 years with 3 out of 4 of the biochemical failures exhibiting recurrent local disease. CONCLUSIONS: PSMA-directed salvage focal reirradiation to the prostate using linear accelerator-based SBRT is feasible and safe. Toxicity was low, with very favorable short term local and biochemical control in a carefully selected cohort of patients.
引用
- Bergamin S, Eade T, Kneebone A, et al. Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32659332. doi:10.1016/j.ijrobp.2020.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。